Identification of metastasis related phosphotyrosine proteins in response to tyrosine kinase inhibitor treatment in human lung cancer cells using label-free quantitative analysis

Identification of metastasis related phosphotyrosine proteins in response to tyrosine kinase inhibitor treatment in human lung cancer cells using label-free quantitative analysis

碩士 === 國立成功大學 === 環境醫學研究所 === 100

Bibliographic Details
Main Authors:	Wen-ChangTzeng, 曾文璋
Other Authors:	Pao-Chi Liao
Format:	Others
Language:	zh-TW
Published:	2011
Online Access:	http://ndltd.ncl.edu.tw/handle/53742724473299540703

Similar Items

Label-free Quantitative Analysis of Tyrosine Phosphoproteome Associated with Lung Cancer Metastasis
by: I-ChiChuang, et al.
Published: (2011)

Toward quantitative phosphotyrosine profiling in vivo
by: Johnson, Hannah, et al.
Published: (2014)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
by: Evan Pisick, et al.
Published: (2004-01-01)

Lung Cancer: Biomarkers, Tyrosine Kinase Inhibitors and Monoclonal Antibodies
by: Made Putra Semadhi, et al.
Published: (2017-09-01)

Identification of tyrosine kinase inhibitors that halt Plasmodium falciparum parasitemia.
by: Kristina Kesely, et al.
Published: (2020-01-01)

TYROSINE KINASE INHIBITORS AND PREGNANCY
by: Elisabetta Abruzzese, et al.
Published: (2014-04-01)

TYROSINE KINASE INHIBITORS AND INTERFERON
by: Maria Dimou, et al.
Published: (2014-01-01)

Elucidating the mechanisms of resistance to tyrosine kinase inhibitors in lung cancer patients
by: Asim Joshi, et al.
Published: (2017-10-01)

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
by: Sun Jin, et al.
Published: (2011-03-01)

Synthesis and Evaluation of Novel Phosphotyrosine Mimetics as Active Site Derivatizing Agents for Protein Tyrosine Phosphatases
by: Yu-Ru Lin, et al.
Published: (2017)

Flavonoids, tyrosine kinase inhibitors, effect on A431 cell growth and metastasis-associated properties
by: Jen-Hsin Huang, et al.
Published: (1999)

Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor
by: Byoung Soo Kwon, et al.
Published: (2020-02-01)

Tyrosine kinase inhibitors in hematological malignancies
by: Kamila Kosior, et al.
Published: (2011-12-01)

Synthesis of new tyrosine kinase inhibitors
by: Sørum, Christopher
Published: (2009)

Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review
by: Shan Su, et al.
Published: (2017-08-01)

Resveratrol Decreases the Resistance of Lung Cancer Cells to EGFR Tyrosine Kinase Inhibitor
by: Chu-Ying Peng, et al.
Published: (2010)

Identification of novel kinases regulating lung cancer metastasis
by: Lara, Romain
Published: (2010)

Tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an unattended need
by: Ximena Gómez, et al.
Published: (2017-06-01)

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016-10-01)

Synthesis of Phosphotyrosine Mimetic-Containing Tri-and Tetrapeptides as SH2 Domain Inhibitors
by: Yi-Ling Hu, et al.
Published: (2010)

Tyrosine kinase inhibitor Tofacitinib. Safety issues
by: G. V. Lukina, et al.
Published: (2015-12-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
by: Yi-fan Chen, et al.
Published: (2011-12-01)

Tyrosine kinase inhibitors and hypothyroidism – an intriguing link
by: Davor Kust, et al.
Published: (2016-06-01)

Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
by: John J. Ryan, MD
Published: (2016-12-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015-09-01)

Targeting tumour microenvironment by tyrosine kinase inhibitor
by: Hor-Yue Tan, et al.
Published: (2018-02-01)

Second-generation inhibitors of Bruton tyrosine kinase
by: Jingjing Wu, et al.
Published: (2016-09-01)

The synthesis of novel inhibitors of protein tyrosine kinases
by: Munawar, Munawar Ali
Published: (1996)

Design and synthesis of protein tyrosine kinase inhibitors
by: Peng, Shao-Zheng, et al.
Published: (1998)

Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer
by: Nikolaos Dervisis, et al.
Published: (2016-01-01)

Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis
by: Lu YY, et al.
Published: (2016-03-01)

Clinical Experience with First-generation Epidermal Growth Factor Receptor  Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients  with Brain Metastasis
by: Huixing DONG, et al.
Published: (2017-02-01)

Quantitative Tyrosine Phosphoproteome Profiling of AXL Receptor Tyrosine Kinase Signaling Network
by: Xinyan Wu, et al.
Published: (2021-08-01)

ManC, Gnd and KpUgd are phosphorylated by tyrosine kinase, KpWzc of Klebsiella pneumoniae-Kinetic analysis of ManC and Gnd, identification of phosphotyrosine residues of KpUgd and search for other phosphorylation target
by: Han-Sheng Chien, et al.
Published: (2008)

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
by: Lynnette Marcar, et al.
Published: (2019-06-01)

Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood–Brain Barrier
by: Eurydice Angeli, et al.
Published: (2021-09-01)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
by: Po-Yen Chen, et al.
Published: (2021-08-01)

Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies
by: Thitinan Aiebchun, et al.
Published: (2021-04-01)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
by: Kenichi Suda, et al.
Published: (2021-06-01)

Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
by: Laksmi Wulandari, et al.
Published: (2018-07-01)